ArticleAdvances in radiation oncology2026
Interim Positron Emission Tomography-Guided Dose-Adapted Residual Site Radiation Therapy Improves Survival in Diffuse Large B-Cell Lymphoma Patients With Partial Metabolic Response After R-CHOP: A Retrospective Cohort Analysis.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Optimal management of diffuse large B-cell lymphoma (DLBCL) patients achieving partial remission (Deauville 5-point scale [5PS]: 4-5) with interim positron emission tomography (iPET) is undefined. This study evaluated iPET-guided, dose-adapted residual site radiation therapy (RSRT) outcomes. Methods and Materials: Retrospective analysis of 68 DLBCL patients with iPET 5-PS 4 to 5 after 4 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) cycles was conducted. Twenty-nine patients received 2 additional R-CHOP + risk-adapted RSRT (24 Gy for 5-PS4; 40 Gy for 5-PS5), while 39 received 2 to 4 R-CHOP cycles without radiation therapy (RT). Results: The RT cohort demonstrated significantly higher end-of-treatment complete response rates (72.4% vs 38.5%; Conclusions: iPET-guided dose-adapted RSRT significantly enhances tumor response and PFS in DLBCL patients with suboptimal interim metabolic response, demonstrating favorable safety. This represents a promising strategy for high-risk partial metabolic responders, warranting prospective validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.